Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sepideh Attal"'
Publikováno v:
Cardiology and Therapy, Vol 13, Iss 2, Pp 369-378 (2024)
Abstract Introduction Tafamidis is the first drug approved by the European Commission for the treatment of wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related
Externí odkaz:
https://doaj.org/article/b41fef91209b4a70bfc1a7d61417730e
Autor:
George Koutitas, Kimberly Nolen, Sepideh Attal, Anastasios Ventouris, Yinnon Dolev, Hans Thijs Van Den Broek
Publikováno v:
IEEE Access, Vol 11, Pp 84430-84439 (2023)
Wild-type transthyretin amyloid cardiomyopathy is an under-recognized cause of heart failure. Pfizer previously developed a machine learning model that performed well in identifying wild-type transthyretin amyloid cardiomyopathy vs. nonamyloid heart
Externí odkaz:
https://doaj.org/article/97ce96d8b0f2479b93fcc8a806c63da8
Autor:
Marc Trossaert, Ségolène Claeyssens-Donadel, Thierry Lambert, Chantal Rothschild, Annie Borel-Derlon, Sepideh Attal, Fabienne Volot
Publikováno v:
Transfusion. 57:1066-1071
BACKGROUND Nonacog alfa, the recombinant Factor IX (F IX) used for the treatment of hemophilia B, was approved in Europe in 1998. A reformulated version was approved for European use in 2007. STUDY DESIGN AND METHODS This postmarketing study, as reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4953d682054d92ce896b31329fb0ab3b
https://doi.org/10.1111/trf.13988
https://doi.org/10.1111/trf.13988
Autor:
Paul Balmer, Ralf Sprenger, Dina Christopoulou, Tin Tin Htar Myint, Damianos Menegas, Eric Bonnet, Sepideh Attal, Harish Madhava
Publikováno v:
Advances in Therapy. 30:127-151
Streptococcus pneumoniae can cause invasive pneumococcal diseases (IPD), such as bacteremic pneumonia, bacteremia, meningitis, and sepsis, and non-IPDs, such as otitis media, nonbacteremic pneumonia, and upper respiratory tract infections. It was est
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3ed75bdc9d54903305df401ed99b1f8
https://doi.org/10.1007/s12325-013-0007-6
https://doi.org/10.1007/s12325-013-0007-6
Autor:
Thierry, Lambert, Chantal, Rothschild, Fabienne, Volot, Annie, Borel-Derlon, Marc, Trossaërt, Ségolène, Claeyssens-Donadel, Sepideh, Attal
Publikováno v:
Transfusion. 57(4)
Nonacog alfa, the recombinant Factor IX (F IX) used for the treatment of hemophilia B, was approved in Europe in 1998. A reformulated version was approved for European use in 2007.This postmarketing study, as recommended by the risk management plan,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e8288b02f0cd831f7256dfa3e1ddc897
https://pubmed.ncbi.nlm.nih.gov/28337764
https://pubmed.ncbi.nlm.nih.gov/28337764